Topical ivermectin improves allergic skin inflammation.

Référence:

Allergy. 2017 Aug;72(8):1212-1221. doi: 10.1111/all.13118. Epub 2017 Feb 6.

Auteurs:

Ventre E1, Rozières A1, Lenief V1, Albert F1, Rossio P2, Laoubi L1, Dombrowicz D3, Staels B3, Ulmann L4, Julia V2, Vial E2, Jomard A2, Hacini-Rachinel F2, Nicolas JF 1 & 1bis, Vocanson M1.

Résumé:

BACKGROUND: Ivermectin (IVM) is widely used in both human and veterinary medicine to treat parasitic infections. Recent reports have suggested that IVM could also have anti-inflammatory properties.

METHODS: Here, we investigated the activity of IVM in a murine model of atopic dermatitis (AD) induced by repeated exposure to the allergen Dermatophagoides farinae, and in standard cellular immunological assays.

RESULTS: Our results show that topical IVM improved allergic skin inflammation by reducing the priming and activation of allergen-specific T cells, as well as the production of inflammatory cytokines. While IVM had no major impact on the functions of dendritic cells in vivo and in vitro, IVM impaired T-cell activation, proliferation, and cytokine production following polyclonal and antigen-specific stimulation.

CONCLUSION: Altogether, our results show that IVM is endowed with topical anti-inflammatory properties that could have important applications for the treatment of T-cell-mediated skin inflammatory diseases.

Découvrez l’équipe Immunologie de l’allergie cutanée et vaccination , co-dirigée par Jean-François Nicolas et Marc Vocanson.

Lien vers la description de l’article dans Pubmed

Paru aussi ce jour sur pubmed de la même équipe:

Eur J Dermatol. 2018 Apr 6. doi: 10.1684/ejd.2018.3231. [Epub ahead of print]

Tolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis.

Delcasso B1bis, Goujon C1bis, Hacard F1bis, Delcroix F1bis, Grande S1bis , Berard F1bis, Nicolas JF 1 & 1bis, Nosbaum A 1 & 1bis.

Lien vers la description de l’article dans Pubmed

Affiliation des Auteurs:

1 CIRI, International Center for Infectiology Research, Université de Lyon, INSERM, U1111, Ecole Normale Supérieure de Lyon, Centre International de Recherche en Infectiologie, Université Lyon 1, CNRS, UMR 5308, Lyon, France.

1bis Allergy and Clinical Immunology Department, University Hospital Lyon Sud, Pierre Bénite, France.

2 Nestlé Skin Health R&D, Sophia-Antipolis, Biot, France.

3 Université de Lille, INSERM, CHU de Lille, European Genomic Institute of Diabetes, Institut Pasteur de Lille, U1011-récepteurs nucléaires maladies cardiovasculaires et diabète, Lille, France.

4 Institut de Génomique Fonctionnelle, CNRS, INSERM, Université de Montpellier, Montpellier, France.

 

NOS TUTELLES ET PARTENAIRES